Biogen Inc - Company Profile
Powered by 
All the sales intelligence you need on Biogen Inc in one solution.
- Save hours of research time with a comprehensive
Sales Intelligence Solution.
- Understand how Biogen Inc fits into your total
addressable market and Ideal Customer Profile.
- Gain competitive edge with triggers that tell you
when and how to engage with Biogen Inc.
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Biogen Inc (Biogen) is a biopharmaceutical company that discovers and develops drugs and biosimilars for the treatment of various neurological and neurodegenerative diseases. The company’s marketed products include Avonex (interferon beta-1a), Vumerity (diroximel fumarate), Fampyra (prolonged-release fampridine tablets), Tysabri (natalizumab), Tecfidera (dimethyl fumarate), and Plegridy (peginterferon beta-1a) for the treatment of multiple sclerosis (MS). It has several product candidates targeting various indications such as MS, Parkinson's disease, Depression, Lupus, CNS and neuromuscular disorders, Amyotrophic Lateral Sclerosis, and Alzheimer’s disease. It also sells Spinraza (nusinersen) for spinal muscular atrophy (SMA); Aduhelm (aducanumab-avwa) for Alzheimer’s disease, and Fumaderm (fumaric acid esters) for severe plaque psoriasis. The company sells its products through a direct sales force, marketing groups, and distributors in the Americas, Europe, Asia, and other territories. Biogen is headquartered in Cambridge, Massachusetts, the US.
Headquarters
United States of America
Address
225 Binney Street, Cambridge, Massachusetts, 02142
Website
www.biogen.com
Telephone
1 781 4642000
No of Employees
7,500
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
BIIB (NASD)
Revenue (2024)
$9.9B
-1.6%
(2024 vs 2023)
EPS
XYZ
Net Income (2024)
XYZ
40.6%
(2024 vs 2023)
Market Cap*
$30.4B
Net Profit Margin (2023)
XYZ
42.9%
(2024 vs 2023)
* As of and is in US$
Biogen Inc premium industry data and analytics
Products and Services
| Products | Brands |
|---|---|
| Avonex (interferon beta-1a) – Multiple Sclerosis | Avonex |
| Plegridy (peginterferon beta-1A) - Multiple Sclerosis | Benepali |
| Fampyra (prolonged-release fampridine tablets) – Multiple Sclerosis | Enbrel |
| XYZ | XYZ |
| XYZ | XYZ |
| XYZ | XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2026 | Contracts/Agreements | In June, the company entered into an agreement to acquire RayThera Inc for US$1 billion. |
| 2026 | Regulatory Approval | In June, the company secured approval from U.S. Food and Drug Administration for salanersen Breakthrough Therapy Designation to treat patients with spinal muscular atrophy. |
| 2026 | Acquisitions/Mergers/Takeovers | In May, the company acquired Apellis Pharmaceuticals, Inc. |
Competitor Comparison
| Key Parameters | Biogen Inc | Eli Lilly and Co | Novartis AG | Bayer AG | Bristol-Myers Squibb Co |
|---|---|---|---|---|---|
| Headquarters | United States of America | United States of America | Switzerland | Germany | United States of America |
| City | Cambridge | Indianapolis | Basel | Leverkusen | Princeton |
| State/Province | Massachusetts | Indiana | Basel-Stadt | Nordrhein-Westfalen | New Jersey |
| No. of Employees | 7,500 | 50,605 | 75,267 | 87,757 | 32,500 |
| Entity Type | Public | Public | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Maria C. Freire | Chairman | Executive Board | 2026 | 71 |
| Christopher A. Viehbacher | Chief Executive Officer; President; Director | Executive Board | 2022 | 66 |
| Robin C. Kramer | Executive Vice President; Chief Financial Officer | Senior Management | 2025 | 60 |
| Guy Hadari | Chief Information Officer | Senior Management | - | - |
| Susan H. Alexander | Executive Vice President; Chief Legal Officer | Senior Management | 2018 | 69 |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer